Management of patients with unclassified epileptic seizures in outpatient clinics in Spain. Results of the RETO study

International Journal of Neuroscience

Volumn 120, Issue 11, 2010, Pages 711-716

  Ngel Mauri Llerda, José ^a   Mercadé Cerd, Juan ^b   Abella Corral, Javier ^c   Pérez Errazquin, Francisco ^d   Quilo, Carlos Ismael Guzmn ^e   Martnez Jiménez, Pedro ^e  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b Hospital Regional Carlos Haya   (Spain)

^c Universidad de La Coruña   (Spain)

^d Neurology Service   (Spain)

^e AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Broad spectrum; efficacy; safety; therapy; treatment; unclassified epilepsy

Indexed keywords

ANTICONVULSIVE AGENT;

ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COMORBIDITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PREGNANCY; QUALITY OF LIFE; SEIZURE; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION REVIEW; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PREGNANCY; QUALITY OF LIFE; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957977320     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2010.517334     Document Type: Article

References (20)

1. Beghi, E. (2004). Effcacy and tolerability of the new antiepileptic drugs: Comparison of two recent guidelines. Lancet Neurology, 3, 618-621.
2. Beydoun, A., & Milling, C. J. (2001). Active-control comparative equivalency monotherapy trials in epilepsy: Are they scientifcally valid? Epilepsy & Behavior, 2, 187-192.
3. Carpay, H. A., Arts, W. F., Geerts, A. T., Stroink, H., Brouwer, O. F., Boudewyn Peters, A. C., et al. (1998). Epilepsy in childhood: An audit of clinical practice. Archives of Neurology, 55, 668-673.
4. Cramer, J. A., Perrine, K., Devinsky, O., & Meador, K. (1996). A brief questionnaire to screen for quality of life in epilepsy: The QOLIE-10. Epilepsia, 37, 577-582.
5. De Silva, M., MacArdle, B., McGowan, M., Hughes, E., Stewart, J., Neville, B. G., et al., (1996). Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carba-mazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet, 347, 709-713.
6. Dupont, S., Marion-Audibert, A. M., Mechin, H., & Sevestre, M. (2006). Newly treated epilepsy: A French observational study. Revista de Neurologia (Paris), 162, 200-207.
7. Fisher, R. S., van Emde Boas, W., Blume, W., Elger, C., Genton, P., & Lee, P. (2005). Epileptic seizures and epilepsy: Defnitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia, 46, 470-472.
8. Guberman, A. (1998). Monotherapy or polytherapy for epilepsy? Canadian Journal of Neurological Sciences, 25, S3-S8.
9. Heller, A. J., Chesterman, P., Elwes, R. D., Crawford, P., Chad-wick, D., Johnson, A. L., et al. (1995). Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomised comparative monother-apy trial. Journal of Neurology, Neurosurgery, and Psychiatry, 58, 44-50.
10. Hindley, D., Ali, A., & Robson, C. (2006). Diagnoses made in a secondary care "fts, faints, and funny turns" clinic. Archives of Disease in Childhood, 91, 214-218.
11. International League Against Epilepsy (ILEA). (1989). Proposal for revised classifcation of epilepsies and epileptic syndromes. Commission on classifcation and terminology of the International League Against Epilepsy. Epilepsia, 30, 389-399.
12. Kellett, M. W., Smith, D. F., Stockton, P. A., & Chadwick, D. W. (1999). Topiramate in clinical practice: First year's post-licensing experience in a specialist epilepsy clinic. Journal of Neurology, Neurosurgery, and Psychiatry, 66, 759-763.
13. Marson, A. G., Kadir, Z. A., Hutton, J. L., & Chadwick, D. W. (1997). The new antiepileptic drugs: A systematic review of their effcacy and tolerability. Epilepsia, 38, 859-880.
14. Perucca, E., & Tomson, T. (1999). Monotherapy trials with the new antiepileptic drugs: Study designs, practical relevance, and ethical implications. Epilepsy Research, 33, 247-262.
15. Pugh, M. J., Foreman, P. J., & Berlowitz, D. R. (2006). Prescribing antiepileptics for the elderly: Differences between guideline recommendations and clinical practice. Drugs & Aging, 23, 861-875.
16. Schneiderman, J. H. (1998). Monotherapy versus polytherapy in epilepsy: A framework for patient management. Canadian Journal of Neurological Sciences, 25, S9-S13.
17. Semah, F., Picot, M. C., Derambure, P., Dupont, S., Vercueil, L., Chassagnon, S., et al. (2004). The choice of antiepileptic drugs in newly diagnosed epilepsy: A national French survey. Epileptic Disorders, 6, 255-265.
18. Shinnar, S., O'Dell, C., & Berg, A. T. (1999). Distribution of epilepsy syndromes in a cohort of children prospectively monitored from the time of their frst unprovoked seizure. Epilepsia, 40, 1378-1383.
19. Vazquez, B. (2004). Monotherapy in epilepsy: Role of the newer antiepileptic drugs. Archives of Neurology, 61, 1361-1365.
20. Viteri, C., Codina, M., Cobaleda, S., Lahuerta, J., Barriga, J., Bar-rera, S., et al. (2008). Validación de la versión española del cues-tionario de calidad de vida en epilepsia QOLIE-10. Neurologia, 23, 157-167.